Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of CYP2C9*3 gene polymorphism on lipid-lowering efficacy of fluvastatin in a Chinese hyperlipidemic population

Zhi-qiang Li¹, Cai-yan Li², Xia Wan¹, Fan Wang¹

¹Department of Neurosurgery, Jingmen No. 1 People's Hospital; ²The Center of Cancer Prevention, Jingmen No. 2 People's Hospital, Jingmen, China.

For correspondence:- Fan Wang Email: 2877695686@qq.com

Accepted: 12 August 2017 Published: 30 September 2017

Citation: Li Z, Li C, Wan X, Wang F. Effect of CYP2C9*3 gene polymorphism on lipid-lowering efficacy of fluvastatin in a Chinese hyperlipidemic population. Trop J Pharm Res 2017; 16(9):2261-2265 doi: 10.4314/tjpr.v16i9.30

© 2017 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the frequency of gene CYP2C9*3 in Chinese populations, and to analyze the impact of CYP2C9*3 genetic polymorphism on the cholesterol-lowering effect of @258;uvastatin in a Chinese hyperlipidemic population.

Methods: CYP2C9 genotype was determined by polymerase chain reaction - restriction fragment length polymorphism (PCR - RFLP) in 270 unrelated hyperlipidemic patients who were treated with 80 mg @258;uvastatin monotherapy daily for 4 weeks and 250 healthy controls. Clinical data were collected prior to treatment with @258;uvastatin and 4 weeks after.

Results: In 270 hyperlipidemic patients, the frequency of CYP2C9*3 was 3.70 % which is significantly higher than in 250 healthy controls (2.60 %) (p < 0.01). After oral intake of @258;uvastatin 80 mg daily for 4 weeks, CYP2C9*1/*3 genotype was associated with a decrease in LDL-C levels (by 33.9 % in CYP2C9*1/*3 versus 24.5 % for CYP2C9*1/*1, p < 0.05) and with reduction of TC (by 36.4 % in CYP2C9*1/*3 versus 19.4 % in CYP2C9*1/*1, p < 0.05).

Conclusion: The frequency of CYP2C9*3 is 3.17 % in Chinese populations, and those who carry CYP2C9*3 mutation have a high risk of hyperlipidemia. CYP2C9*3 seems to increase the lipid-lowering effects of @258;uvastatin.

Keywords: Hyperlipidemia, Gene, CYP2C9, Polymorphism, Polymerase chain reaction, Restriction fragment length polymorphism, Fluvastatin